Pfizer's Sutent improves survival in cancer study (Reuters)


Reuters - Pfizer Inc.'s experimental drug
Sutent improved survival and reduced tumor growth in patients
with a type of stomach cancer, according to a pivotal-stage
trial the company unveiled this weekend.

Read more...